首页> 美国卫生研究院文献>other >Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar
【2h】

Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar

机译:成人脑肿瘤联盟(ABTC)I-125球囊近距离放射治疗在高级别神经胶质瘤中的预期剂量查找试验的结果:当MRI治疗效果和复发表现相似时临床试验设计和技术开发面临的挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectivesThe aim of this study is to define the maximal safe radiation dose to guide further study of the GliaSite balloon brachytherapy (GSBT) system in untreated newly diagnosed glioblastoma (NEW-GBM) and recurrent high-grade glioma (REC-HGG). GBST is a balloon placed in the resection cavity and later filled through a subcutaneous port with liquid I-125 Iotrex, providing radiation doses that diminish uniformly with distance from the balloon surface.
机译:目的本研究的目的是确定最大安全放射剂量,以指导对未经治疗的新诊断的胶质母细胞瘤(NEW-GBM)和复发性高级别胶质瘤(REC-HGG)进行GliaSite气囊近距离放射治疗(GSBT)系统的进一步研究。 GBST是一个放置在切除腔中的球囊,随后通过皮下端口用液体I-125 Iotrex填充,其放射剂量随与球囊表面的距离而均匀减小。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号